For our UK readers, we hope you avoided the flooding. Here are a few stories you may have missed whether you were evacuating or simply focused on the last Harry Potter ...
- And then there was one. Of Europe's five big pharma, only Novartis' Dan Vasella will have survived as CEO by next summer, Reuters reports. Roche's recent decision to replace Franz Humer at CEO with Severin Schwan may also put pressure on Novartis to likewise split its chairman/CEO positions. Word on the street is that Vasella may groom vaccines head Joerg Reinhardt as a successor.
- They grow up so fast. Tysabri turns one today, sort of. The MS therapy returned to the US market one year ago. Elan and Biogen Idec estimate 14,000 patients receive the infused treatment.
- The quick brown fox jumps over the lazy catheter (or something like that). EV3 is buying Fox Hollow for $780 million in cash and stock. The companies have been working together in peripheral artery disease since early 2007. More to come on this story.
- And the New York Times profiles the Cleveland Clinic's Steve Nissen. Naderesque? OK, maybe consumer rights crusader Nader, not election swaying Nader.